|
|
|
|
Diabetes Cell Biology: New diabetes cell biology data have been reported by researchers at University libre of Bruxelles
Today's Medical & Research News New data have been reported by researchers at University libre of Bruxelles March 18th, 2010 Printer-Friendly Version City:Brussels Country:Belgium Cell Biology Cytokines Gastroenterology Interferon Necrosis Pancreas Therapy...
|
|
|
Lymphoma Tumor Suppressor Enhances Growth of Brain Tumors
While the A20 protein (tumor necrosis factor, alpha-induced protein 3 or TNFAIP3) is known to be tumor suppressive in lymphoma, a recent study has found that in glioblastoma, an aggressive type of brain tumor, A20 acts as a potent tumor enhancer.
|
|
|
Europe shares edge up on drugmakers; Adidas gains
* FTSEurofirst 300 index up 0.1 pct * Drugmakers gain; GlaxoSmithKline rises * Adidas up on upbeat Nike results * For up-to-the-minute market news, click on [STXNEWS/EU] LONDON, March 18 (Reuters) - European shares edged up on Thursday after hitting 17-month...
|
|
|
Anti-TNF-Alpha Therapy With Infliximab in Spondyloarthritides
Do the benefits of anti-TNF therapy in ankylosing spondylitis outweigh the short Anti-TNF-Alpha Therapy With Infliximab in Spondyloarthritides.
|
|
|
UltraCap H.D. Capsule In 40-Inch Length Provides Large Volume Filtration
UltraCap H.D.(Heavy Duty) single-use high capacity capsule filters provide high flow rates and high throughput, in lengths up to 40 inches (100 cm) for large volume filtration. The robust UltraCap H.D. resists damage due to rough handling conditions and...
|
|
|
GlobeImmune Announces Presentations of GI-5005 Phase 2b Data at EASL 2010 Meeting
Sustained Virologic Response, Pharmacogenomic and Biopsy Analysis of HCV Patients Receiving GI-5005 Therapeutic Vaccine to be Presented at the Annual Meeting of the European Association for the Study of the Liver LOUISVILLE, Colo., March 17, 2010 - GlobeImmune...
|
|
|
Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma
Miyake Y et al.Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma.
|
|
|
Interferon-alpha: A Therapeutic Target in Systemic Lupus Erythematosus
Crow MK The explosion of data and understanding related to the IFN pathway in SLE have readied the lupus community for translation of those insights to improved patient care.Patience will be needed to allow collection of clinical data and biologic specimens...
|
|
|
GlobeImmune Announces Presentations of GI-5005 Phase 2b Data at EASL 2010 Meeting
Sustained Virologic Response, Pharmacogenomic and Biopsy Analysis of HCV Patients Receiving GI-5005 Therapeutic Vaccine to Be Presented at the Annual Meeting of the European Association for the Study of the Liver GlobeImmune Inc.today announced that three...
|
|
|
Tuberculosis Therapy: New tuberculosis therapy data have been reported by researchers at University Estadual da Paraiba
Today's Medical & Research News Tuberculosis Therapy New tuberculosis therapy data have been reported by researchers at University Estadual da Paraiba March 18th, 2010 Printer-Friendly Version City:Campina Grande Country:Brazil Tuberculosis Therapy...
|
|
|
MedAppz Integrates Alpha II's Codewizard With iSuite
Alpha II, a leader in healthcare coding, compliance and reimbursement, announced a contract with MedAppz to integrate Alpha IIs CodeWizard software with iSuite.Were excited about the introduction of CodeWizard to the MedAppz iSuite, said Stuart...
|
|
|
Alpha IIs CodeWizard software to be integrated with MedAppz' iSuite
Alpha II, a leader in healthcare coding, compliance and reimbursement, announced today a contract with MedAppz to integrate Alpha IIs CodeWizard software with iSuite.This integration of technologies will allow iSuite users to generate evaluation...
|
|
|
Immune response of DNA vaccine against lymphocystis disease virus and expression analysis of immune-related genes after vaccination
In this study, we found that an intramuscular injection of Japanese flounder (Paralichthys olivaceus, 60[ndash]80 g in weight and 15[ndash]20 mL in length) with 5 [mu]g of a DNA vaccine (pEGFP-N2-LCDV-cn-MCP 0.6 kb, containing lymphocystis disease virus major...
|
|
|
Leading Dermatologist Recommends a Moisturizer With 12% Alpha-Hydroxy to Soften the Often Neglected Neckline
Companies mentioned in this article: Upsher-Smith Laboratories, Inc.MAPLE GROVE, Minn., March 17 /PRNewswire/ -- The neckline is often neglected when it comes to regular skin care, but it can be the first place to show signs of aging according to leading...
|
|
|
Idera Pharmaceuticals Announces Acceptance of IMO-2125 Abstracts ...
Company: Idera Pharmaceuticals Inc (IDRA) Idera Pharmaceuticals, Inc.(Nasdaq: IDRA) today announced that two abstracts related to its Toll-like Receptor 9 (TLR9) agonist, IMO-2125, were accepted for presentation at the 45th Annual Meeting of the European...
|
|
|
Idera Pharmaceuticals Announces Acceptance of IMO-2125 Abstracts for Presentation at EASL Annual Meeting
IMO-2125 Oral Presentation: "A Phase 1, Multi-Center, Randomized, Placebo-controlled, Dose-escalation Study of IMO-2125, a TLR9 Agonist, in Hepatitis C Non-responders"; Thursday, April 15, 2010, 5:15 -- 5:30 p.m.IMO-2125 Poster Presentation: "IMO-2125, an...
|
|
|
Human Genome Sciences announces Phase 2 results of mapatumumab combination therapy for NSCLC
Peginterferon alpha-2a yields better results in treating patients with chronic hepatitis CIn patients with chronic hepatitis C, treatment with peginterferon alpha-2a (PegIFN2a) plus ribavir...Daily dose of pistachios may help reduce risk of lung...
|
|
|
Breast Cancer Banquet at Miami University
Come help raise funds for a good cause!Miami University Shriver Program Board and Zeta Tau Alpha will be hosting the 11th Annual Breast Cancer Banquet! The banquet will be raising funds by silent auction. There will be a keynote speaker, which will...
|
|
|
Idera Pharmaceuticals Announces Acceptance of IMO-2125 Abstracts for Presentation at EASL Annual Meeting
CAMBRIDGE, Mass.-- (BUSINESS WIRE) -- (Nasdaq: IDRA) today announced that two abstracts related to its Toll-like Receptor 9 (TLR9) agonist, IMO-2125, were accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the...
|
|
|
Idera Pharmaceuticals Announces Acceptance of IMO-2125 Abstracts for Presentation at EASL Annual Meeting
Idera Pharmaceuticals, Inc.(IDRA) today announced that two abstracts related to its Toll-like Receptor 9 (TLR9) agonist, IMO-2125, were accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in...
|
|
|
Idera Pharmaceuticals Announces Acceptance of IMO-2125 Abstracts for Presentation at EASL Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc.(Nasdaq: IDRA) today announced that two abstracts related to its Toll-like Receptor 9 (TLR9) agonist, IMO-2125, were accepted for presentation at the 45th Annual Meeting of the European...
|
|
|
Idera Pharmaceuticals Announces Acceptance of IMO-2125 Abstracts for Presentation at EASL Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc.(Nasdaq: IDRA - News) today announced that two abstracts related to its Toll-like Receptor 9 (TLR9) agonist, IMO-2125, were accepted for presentation at the 45th Annual Meeting of the European...
|
|
|
Idera Pharmaceuticals Announces Acceptance of IMO-2125 Abstracts for Presentation at EASL Annual Meeting
CAMBRIDGE, Mass.(BUSINESS WIRE) Idera Pharmaceuticals, Inc.(Nasdaq: IDRA) today announced that two abstracts related to its Toll-like Receptor 9 (TLR9) agonist, IMO-2125, were accepted for presentation at the 45th Annual Meeting of the European Association...
|
|
|
Idera Pharmaceuticals Announces Acceptance of IMO-2125 Abstracts for Presentation at EASL Annual Meeting
Idera Pharmaceuticals, Inc.(Nasdaq: IDRA) today announced that two abstracts related to its Toll-like Receptor 9 (TLR9) agonist, IMO-2125, were accepted for presentation at the 45 th Annual Meeting of the European Association for the Study of the Liver (EASL...
|
|
|
Idera Pharmaceuticals Announces Acceptance of IMO-2125 Abstracts for Presentation at EASL Annual Meeting
CAMBRIDGE, Mass.- (Business Wire) Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that two abstracts related to its Toll-like Receptor 9 (TLR9) agonist, IMO-2125, were accepted for presentation at the 45th Annual Meeting of the European...
|
